Fig. 4

Statistical analysis of relative abundance of IBP2_LEG, IBP2_LIQ, and TIMP1_GFQ peptides in patients’ serum samples. A IBP2_LEG peptide. B IBP2_LIQ peptide. C TIMP1_GFQ peptide. D A combination of IBP2_LEG and IBP2_LIQ. A post-hoc test was used for pairwise comparison of the abundance of peptides from non-cancerous, benign ovarian condition (benign), early-stage HGSOC (early-stage), and late-stage HGSOC (late-stage) sera. The abundance indicates the on-column concentration based on a 10 µL injection volume. * indicates p < 0.05 and ** indicates p < 0.01